baber/WOPTO huggingface dataset:
Patent NZ-337921-A (NZ)
Title: Process for synthesizing phosphodiesters via a bis (amino) phophino intermediate
Inventor: AMEDIO JOHN C
IPC: C07F9/117
Filed: 1998-01-27
Abstract: This process is for the production of phosphodiester compounds having the formula, R-O-P(O)(OH)-O-R1 where R and R1 are each, aliphatic, aryl, heterocyclic, peptidic or neucleosidic.  The process take place in a single reaction vessel and comprises reaction of an alcohol ROH with PCl3 to form a dichloophosphine compound, followed by coupling with an amine base to form a bis(amino)phosphino compounds, then further coupling of the bis(amino)phosphino compound with a second alcohol R1OH to form an aminophosphino compound, and then finally subjecting the aminophosphino compound to hydrolysis and oxidation. These compounds are particularly useful as contrast agents for diagnostic imaging. The process avoids the need for multiple isolation and purification steps otherwise reduced due to the formation of multiple intermediates.
Patent NZ-500203-A (NZ)
Title: Debugging interactive TV application by running it on decoder emulator
Inventor: LIAO HONGTAO
IPC: H04N17/00
Filed: 1997-04-25
Abstract: A method of developing and testing a control program for a MPEG decoder involves writing an initial program on a workstation, and passing it to an emulator which emulates a domestic set-top decoder.  The running of the control program is controlled by signals from the workstation.  These signals enable the programmer to stop and start the control program, and command the emulator to send data back to the workstation so that the programmer can assess whether the program is working correctly.
Patent NZ-506435-A (NZ)
Title: 3-Indoly-2-hydroxy-4-oxo-2-butanoic acid useful as antiviral activity
Inventor: FUJISHITA TOSHIO
IPC: C07D249/08
Filed: 1999-03-26
Abstract: An indole derivative or a tautomer, or a pharmaceutically acceptable salt, or a hydrate thereof has the formula (I) wherein: R1 is hydrogen, alkyl, cycloalkylalkyl, alkylsulphonyl, alkylcarbonyl, or optionally substituted aryl, aralkyl, arylsulphonyl, arylcarbonyl, heteroaryl, heteroaralkyl, heteroarylsulphonyl, alkoxycarbonyl, sulphamoyl, or carbamoyl; R2 is hydrogen, alkyl, alkylcarbonyl, or optionally substituted aryl, aralkyl, arylcarbonyl, heteroaryl, heteroaralkyl, arylthio, arylsulphinyl, arylsulphonyl, heterocyclyl alkyl, or heterocyclyl sulphonyl; R3, R4, R5 and R6 are independently hydrogen, halogen, trihalogenated alkyl, hydroxy, alkoxy, nitro, amino, optionally esterified carboxy, optionally substituted aralkyloxy, or optionally substituted arylsulphfonyloxy; X is hydroxy or optionally substituted amino; Y is COOR optionally substituted aryl, or optionally substituted heteroaryl and R is hydrogen or an ester residue provided that a compound wherein R1, R2, R3, R5, and R6 each is hydrogen; R4 is hydrogen, methoxy, or chloro; X is hydroxy; and Y is COOC2H5 is excluded. A pharmaceutical composition thereof is useful for treating viral infections such as HIV.
Patent NZ-508414-A (NZ)
Title: Compositions and methods for alleviating impaired mental function, memory loss and reducing recovery time in anaesthetized mammals
Inventor: JANUS CHRISTOPHER GEORGE
IPC: A61P25/28
Filed: 1999-05-20
Abstract: Composition and methods of alleviating impaired mental function and memory loss in mammals and reducing the recovery time from anaesthesia in age mammals, comprising treating the mammal with a non-toxic, enhancing effective amount of a cell membrane permeant calcium buffer, wherein the buffer is preferably a calcium ion chelating agent having a KD selected from the range 1x10-4 to 1x10-8 Molar and being essentially calcium ion-selective over other metal ions. A most preferred cell membrane permeant calcium buffer is bis (O-aminophenoxy)-ethane-N,N,N,N-tetraacetic acid-acetoxymethyl ester (BAPTA-AM).
Patent NZ-513097-A (NZ)
Title: Cyclic substituted fused pyrrolocarbazoles and isoindolones
Inventor: TRIPATHY RABINDRANATH
IPC: A61P/
Filed: 2000-02-11
Abstract: The present invention discloses cyclic substituted fused pyrrolocarbazoles and isoindolones having formula I (see below). The invention also is directed to methods for making and using the cyclic substituted fused pyrrolocarbazoles and isoindolones. The compounds disclosed are useful as pharmaceutical agents for the treatment of prostate disorders, neoplasia, AIDS, arthritis, pulmonary fibrosis, myelofibrosis, artherosclerosis and brain or spinal chord injuries or diseases. The compound is also useful for regulating protein kinases. Treating or preventing pathology associated with VEGFR, PDGFR, mixed lineage kinase, FGFR activity.
Patent NZ-514982-A (NZ)
Title: Method for the preparation of citalopram
Inventor: PETERSEN HANS
IPC: C07D307/87
Filed: 1999-11-19
Abstract: A method for the preparation of citalopram comprising reaction of a compound 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran (formula IV) Wherein R is Cl or Br; with a cyanide source in the presence of a nickel catalyst and isolation of the corresponding 5-cyano compound (citalopram).
Patent NZ-529862-A (NZ)
Title: A deadlock arrangement for locks
Inventor: KEIGHTLEY KYM JOHN
IPC: E05C1/14
Filed: 2003-11-28
Abstract: A deadlocking assembly for use in locks that includes a rack supporting a bolt and a driving or pinion gear that drive the rack. Both the rack and the pinion gear have teeth that intermesh. The pinion gear further includes two arms one of which acts as a stop when extending the bolt and the other that acts as a deadlock. When in the deadlocked position forcing of the bolt to prevented by the other arm since the pinion gear teeth and the rack gear teeth at the position do not intermesh. A tab is further used to limit further rotation of the pinion gear.
Patent NZ-530213-A (NZ)
Title: Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
Inventor: BABISH JOHN G
IPC: A23L1/30
Filed: 2002-06-20
Abstract: Disclosed is a pharmaceutical grade extract of hops comprising an effective amount of component I selected from the group consisting of alpha acids and beta acids and an effective amount of at least one component II selected from the group consisting of alpha acids, beta acids, essential oils (as defined herein), fats and waxes, with the proviso that component I and II are not the same compound, wherein said pharmaceutical grade extract comprises from about 10 to 95 percent by weight of alpha-acid and a pharmaceutically acceptable carrier; Further disclosed is the use of the above pharmaceutical grade extract of hops in the manufacture of a medicament for use in the alleviation of the symptoms of inflammation.
Patent NZ-532515-A (NZ)
Title: Compositions comprising a RANKL peptide attached to a core or virus-like particle for treatment of bone disease and immunization
Inventor: BUCHMANN MARTIN
IPC: A61K38/095
Filed: 2002-11-07
Abstract: A composition is described that comprises a virus-like particle (VLP) and at least one antigen or antigenic determinant wherein the antigen or antigenic determinant is a RANKL protein, RANKL fragment or RANKL peptide, and the antigen is bound to the VLP. Preferably the VLP is selected from recombinant proteins of: hepatitis B virus, measles virus, Sindbis virus, Rotavirus, Foot-and-Mouth-Disease virus, Retrovirus, Norwalk virus, Alphavirus, human Papilloma virus, Polyoma virus, bacteriophages, RNA-phages and Ty. The composition is useful for treating or preventing bone diseases. Also described is a method of immunizing non-human animals using the composition.
Patent NZ-534704-A (NZ)
Title: Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
Inventor: BLAKELY WILLIAM
IPC: A61K31/167
Filed: 2003-02-12
Abstract: An anti-parasitic composition is disclosed, which contains an effective amount of a salicylanilide anti-parasitic compound together with a polymeric species selected from the group consisting of polyvinylpyrrolidones, and polyoxypropylene/polyoxyethylene block copolymers, in an amount in the range of from 1% to 35% (w/v) that is effective to provide blood plasma levels of the said compound greater than about 20 ppm over a period of treatment, and an effective amount of at least one other anti-parasitic compound selected from the group consisting of avermectins and milbemycins, in a physiologically acceptable solvent (wherein the solvent may be selected from the group consisting of glycerol formal, propylene glycol, polyethylene glycol and water and combinations thereof).
Patent NZ-537049-A (NZ)
Title: Cup-shaped receptacle and lid that has inverted U shape having constriction that clips over receptacle bead
Inventor: D AMATO GIANFRANCO
IPC: B65D41/18
Filed: 2002-12-19
Abstract: A cup-shaped receptacle (c) has an outer bead (10) in its opening area for clipping on a plastic lid (D). The lid has a circumferentially continuous clamping groove (1) for receiving the bead. The clamping groove is continued outwards by an elastically deformable constriction (14), and inwards by an outer wall (6) of a circumferentially continuous, U-shaped lid recess, the U-web of which is situated below the height position of the constriction and the inner leg wall of which forms a part of a dome which extends upwardly beyond the height position of the constriction. The lid recess extends downwards beyond the height position of the constriction and has an outer diameter at its outer surface which is adapted to the inner diameter of the receptacle wall such that the lid recess functions at least as a centring and guide projection for the lid-clip-on action, which projection slidingly co-operates with the receptacle wall already at least while the bead passes the constriction.
Patent NZ-538285-A (NZ)
Title: Overhead packaging cushion supply system
Inventor: SADAKIERSKI WALTER C
IPC: B65B55/20
Filed: 2005-02-16
Abstract: Disclosed is a system for supplying packaging cushions manufactured from cushion feedstock, the system comprising a lift, a cushion-supply machine moveably supported by the lift, and a hopper. The hopper defines an entrance opening for receiving packaging cushions from the cushion-supply machine into the hopper and an exit for withdrawing cushions from the hopper, wherein the elevation of the hopper entrance opening is higher than the elevation of the hopper exit opening. The cushion-supply machine defines a cushion outlet. The lift is adapted to move the cushion-supply machine between a supply position, in which the elevation of the cushion outlet is higher than the elevation of the hopper entrance opening, and a reload position in which the elevation of the cushion-supply machine cushion outlet is lower than the elevation of the hopper entrance opening.
Patent NZ-539813-A (NZ)
Title: A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
Inventor: PAU MARIA GRAZIA
IPC: C12N15/30
Filed: 2003-12-16
Abstract: Disclosed is a vaccine against malaria infections, based on recombinant adenoviruses viruses. The recombinant viral-based vaccine can be applied for immunization against Plasmodium infections, such as infections by P. falciparum. Codon-optimized circumsporozoite (CS) genes are disclosed (Seq Id No 4 and 6). Preferably, replication-defective adenoviruses are used, derived of serotypes (Ad11, Ad26, Ad34, Ad35, Ad48, Ad49 and Ad50) that encounter low titers of neutralizing antibodies.
Patent NZ-544505-A (NZ)
Title: Fluid mixing apparatus with valve operated by pulse width modulation driver(s) via controller sensing oxygen content, useful in hypoxic training apparatus
Inventor: POTTER BRUCE
IPC: B01F23/10
Filed: 2006-01-24
Abstract: A fluid mixing apparatus is provided. The apparatus has a mixing volume (10), a primary inlet (7), secondary inlet (9), and an outlet (19) are provided for the volume. The secondary inlet (9) includes a valve (12) which is adapted to be operated by a driver to pulse width modulate the valve between two flow states to achieve a given flow state through the secondary inlet (9). A controller (17) is adapted to provide a control signal for the driver and to read at least one oxygen content value related to at least one portion of a duty cycle related to that oxygen content.
Patent NZ-546266-A (NZ)
Title: Pyrimidin-2-amine derivatives and their use as A2B adenosine receptor antagonists
Inventor: VIDAL JUAN BERNAT
IPC: C07D471/04
Filed: 2004-09-22
Abstract: Disclosed are compounds of formula (I), wherein the substituents are as defined in the specification. The compounds are useful for the treatment of asthma, bronchoconstriction, allergic diseases, hypertension, atherosclerosis, reperfusion injury, myocardial ischemia, retinopathy, inflammation, gastrointestinal tract disorders, cell proliferation disorders, diabetes mellitus, and autoimmune diseases.
Patent NZ-547121-A (NZ)
Title: New phenylpyridilpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
Inventor: DESOS PATRICE
Filed: 2006-05-11
Abstract: Disclosed are compounds of formula (I) wherein: R1 represents and NR3SO2R4 group; R3 represents an H atom or a linear or branched alkyl group; R4 represents a linear or branched alkyl group, an aryl group or an NR5R6group where R5 and R6 are as defined; and R2 represents a linear or branched alkyl group, cycloalkyl group or a cycloalkyl-alkyl group wherein the alkyl moiety may be linear or branched. Compounds of the type disclosed specifically interact with H3 histamine receptors and can be used in the treatment of neuropathologies associated with cerebral ageing, mood disorders, eating behaviour, sleep-wakefulness rhythm and of attention deficit hyperactivity syndrome.
Patent NZ-547696-A (NZ)
Title: Pyrazole derivatives as protein kinase modulators
Inventor: BERDINI VALERIO
IPC: C07D413/10
Filed: 2004-12-23
Abstract: Disclosed are pyrazole derivative compounds of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the inker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R1 is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the specification. Also disclosed are pharmaceutical compositions containing these compounds, methods for preparing these compounds and their use as anticancer agents.
Patent NZ-554753-A (NZ)
Title: Semi-soft c-class immunostimulatory oligonucleotides
Inventor: KRIEG ARTHUR M
IPC: A61K9/00
Filed: 2005-10-20
Abstract: Provided is an immunostimulatory oligonucleotide comprising: 5' TC_GTC_GTN1TC_GGCGCN1GCCG 3', wherein the oligonucleotide includes at least 2 stabilized inter-nucleotide linkages and _ represents phosphodiester or phosphodiester-like inter-nucleotide linkage and wherein N1 is 3 nucleotides in length, with N referring to any nucleotide. Further provided are variants of the oligonucleotide and use of the oligonucleotides in the manufacture of medicaments for treating asthma, allergy, cancer and infectious diseases as well as viral disorders.
Patent NZ-562000-A (NZ)
Title: Inhaler device counter
Inventor: BOWMAN NIC
IPC: G06M1/08
Filed: 2006-04-10
Abstract: An inhaler counter has a ratchet wheel 230 rotated by oscillation of a pawl 500 to convert a linear actuation motion into a rotational motion to advance a dose count display. To accomplish a crisp disengagement of the pawl from the ratchet so that the ratchet is only turned a precise amount for each actuation of the pawl, the opposing faces 530 of the pawl and 520 of the ratchet wheel following after each tooth in the direction of rotation of the ratchet wheel are shaped to establish abutment of the respective faces at a lever point L.
Patent NZ-563455-A (NZ)
Title: Post-transcriptional regulation of gene expression in plants using a destablising sequence selected from a 3'SAUR terminator, a DST element, an ATTTA motif, an ATTTAA motif or a combination of ATTTA and ATTTAA motifs
Inventor: THAI KWAN Y
IPC: C12N15/82
Filed: 2006-05-16
Abstract: Disclosed is a method to post-transcriptionally decrease message stability of an exogenous gene of interest in a seed of a crop plant. The method comprises expressing said exogenous gene in a seed tissue, wherein said gene comprises a destabilising sequence in the 3' untranslated region, whereby message stability of said gene of interest is post-transcriptionally decreased in the seed. The destabilising sequence of the disclosed method comprises a 3'SAUR terminator, a DST element, an ATTTA motif, an ATTTAA motif or a combination of ATTTA and ATTTAA motifs.
Patent NZ-564129-A (NZ)
Title: Phosphopeptide or phosphoprotein stabilised amorphous calcium complexes
Inventor: REYNOLDS ERIC CHARLES
IPC: A61Q11/00
Filed: 2006-06-23
Abstract: Disclosed is a phosphopeptide or phosphoprotein (PP) stabilised amorphous calcium phosphate or amorphous calcium fluoride phosphate complex having a calcium ion content greater than about 30 moles of calcium per mole of PP. Also disclosed is a method for producing the above complex, comprising obtaining a solution including a PP-ACP and/or PP-ACFP complex; and mixing with calcium and phosphate ions, while maintaining the pH of the solution at less than 7. Also disclosed is the use of the above complex in oral care for remineralizing a dental surface or substrate, and for treating dental caries, dental erosion/corrosion, dental hypersensitivity and dental calculus.
Patent NZ-566742-A (NZ)
Title: Process and apparatus for removal of sour species from a natural gas stream
Inventor: HART ALLAN
IPC: F25J3/08
Filed: 2006-09-15
Abstract: Disclosed is a process for removing a sour species from a dehydrated natural gas feed stream comprising the steps of: (a) cooling the dehydrated natural gas feed stream and forming a slurry of solid sour species and hydrocarbon liquids, and a gaseous stream containing gaseous sour species; (b) separating the gaseous stream containing gaseous sour species and the slurry; and, (c) treating the gaseous stream containing gaseous sour species with a liquid solvent and forming a dehydrated sweetened gas stream and a liquid solution of the sour species.
Patent NZ-570997-A (NZ)
Title: Buprenorphine derivatives and uses thereof
Inventor: CHAPLEO CHRISTOPHER BOURNE
IPC: A61K31/485
Filed: 2007-03-27
Abstract: Disclosed are di-esters of 21-(cyclopropy1-7alpha-[(S)-1-hydroxy-1, 2, 2-trimethylpropyl]- 6,14- endo-ethano-6,7,8,14-tetrahydro-oripavine of Structure I, or salts thereof wherein R1 is (1) an alkylene, (2) -(CH2)pCH=CH(CH2)p-, in which each p is independently an integer from 0 to 4, or (3) is defined in the specification for treating for relieving or treating moderate to severe pain, opiate abuse and/or dependence in a subject.
Patent NZ-574568-A (NZ)
Title: Production of high tryptophan maize by chloroplast targeted expression of anthranilate synthase
Inventor: MANJUNATH SIVA
IPC: A23L11/00
Filed: 2007-08-09
Abstract: An expression vector for increasing tryptophan production in a plant. The vector comprises a polynucleotide molecule encoding a chloroplast transit peptide (CTP) fused to a monomeric anthranilate synthase, wherein; (a) the CTP comprises the polypeptide sequence of SEQ ID NO: 21, 22, 28, 32, 33 or 36; or (b) the polynucleotide molecule encoding the CTP comprises SEQ ID NO: 2, 3, 9, 13, 14 or 17. The CTP provides enhanced targeting of the monomeric anthranilate synthase to the chloroplast of the plant cell when compared with the targeting of the anthranilate synthase by chloroplast transit peptide 1 (CTP1).
Patent NZ-575327-A (NZ)
Title: Wireless device and method
Inventor: WEIR ALEXANDER
IPC: H04B1/16
Filed: 2007-08-17
Abstract: A wireless device and a method for performing background scanning of one or more radio channels in a wireless network are disclosed. The wireless device comprises a transceiver adapted to transmit a signal to one or more other devices on the network. The signal is indicative that the device is intending to enter a pre-defined hibernation mode. The transceiver is further adapted to perform background scanning of the one or more radio channels when the one or more other devices consider the device to be in a hibernation mode.
Patent NZ-575426-A (NZ)
Title: Quinazolinone and isoquinolinone acetamide derivatives useful for the treatment of disorders which are influenced by modulation of the activity of the hpa axis
Inventor: SCHULZ JURGEN
IPC: A61K31/472
Filed: 2007-09-10
Abstract: Provided herein are quinazolinone and isoquinolinone derivatives of formula (I), wherein substituents are as described in the specification. Also disclosed is the use of a compound of formula (I) for the preparation of a medicament intended for the treatment of disorders or diseases which are influenced by modulation of the activity of the HPA axis (ie stress related disorders or depression).
Patent NZ-578703-A (NZ)
Title: Dominant gene suppression transgenes and methods of using same
Inventor: CIGNAN ANDREW M
IPC: C12N15/82
Filed: 2004-12-16
Abstract: Disclosed is a method of preventing transmission of a transgene of interest through the male gametes of a non-human transgenic organism, comprising linking said transgene to a nucleotide sequence encoding a product that inhibits the formation, function, or dispersal of male gametes, and wherein the gene product degrades starch or interferes with starch accumulation in the male gametes.
Patent NZ-580224-A (NZ)
Title: High frequency oscillation respiratory therapy device
Inventor: DUNSMORE THOMAS J
IPC: A61M16/00
Filed: 2008-04-02
Abstract: A respiratory therapy device is disclosed. The device comprises a housing, a flow diverter, a high frequency pressure port, and an entrainment port. The housing defines a primary passageway which has a patient interface side. The flow diverter structure is maintained by the housing in fluid communication with the primary passageway opposite the patient interface side. The flow diverter structure is characterized by the absence of a venturi tube. The high frequency pressure port is maintained by the housing and configured for fluid connection to a source of oscillatory gas flow. The high frequency pressure port is fluidly associated with the flow diverter structure. The entrainment port is maintained by the housing and openable to ambient air and fluidly associated with the flow diverter structure. The device is configured such that flow characteristics of gas flow from an external source are altered upon interacting with the flow diverter structure to create a pressure drop for drawing in ambient air through the entrainment port in delivering a percussive pressure therapy to the patient interface side of the primary passageway.